Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Reactivating antitumor efficacy of anti-PD-1 therapy with MRx0518

Alex Stevenson, PhD, 4D Pharma plc, Leeds, UK, discusses an ongoing trial (NCT03637803) of MRx0518 in combination with pembrolizumab, an anti-PD-1 checkpoint inhibitor, in patients with secondary resistance to pembrolizumab. MRx0518 is a single-strain live biotherapeutic product with anti-tumorigenic efficacy. Promising interim results demonstrate the immunostimulatory benefits of MRx0518 as a monotherapy but also in reactivation of previous checkpoint blockade therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.